Brad Canino
Stock Analyst at Guggenheim
(3.83)
# 521
Out of 5,050 analysts
19
Total ratings
56.25%
Success rate
11.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brad Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PYXS Pyxis Oncology | Maintains: Buy | $5 → $7 | $3.91 | +79.03% | 2 | Nov 4, 2025 | |
| KYMR Kymera Therapeutics | Assumes: Buy | $90 | $58.83 | +52.98% | 1 | Nov 3, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Buy | $40 | $18.18 | +120.02% | 2 | Oct 22, 2025 | |
| CGON CG Oncology | Initiates: Buy | $90 | $39.68 | +126.81% | 1 | Oct 8, 2025 | |
| OLMA Olema Pharmaceuticals | Initiates: Buy | $20 | $8.35 | +139.52% | 1 | Oct 8, 2025 | |
| CELC Celcuity | Initiates: Buy | $110 | $74.52 | +47.61% | 1 | Sep 22, 2025 | |
| ORIC ORIC Pharmaceuticals | Assumes: Buy | $18 | $12.35 | +45.75% | 1 | Sep 4, 2025 | |
| RLAY Relay Therapeutics | Assumes: Buy | $15 | $6.05 | +147.93% | 1 | Sep 4, 2025 | |
| NUVL Nuvalent | Assumes: Buy | $122 | $93.35 | +30.69% | 1 | Sep 4, 2025 | |
| CCCC C4 Therapeutics | Initiates: Buy | $8 | $2.34 | +241.88% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $72 | $26.48 | +171.90% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $9.86 | - | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $3.89 | +105.66% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $450 | $8.41 | +5,250.77% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $16.46 | +234.14% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $40.81 | -26.49% | 2 | Mar 31, 2021 |
Pyxis Oncology
Nov 4, 2025
Maintains: Buy
Price Target: $5 → $7
Current: $3.91
Upside: +79.03%
Kymera Therapeutics
Nov 3, 2025
Assumes: Buy
Price Target: $90
Current: $58.83
Upside: +52.98%
Summit Therapeutics
Oct 22, 2025
Reiterates: Buy
Price Target: $40
Current: $18.18
Upside: +120.02%
CG Oncology
Oct 8, 2025
Initiates: Buy
Price Target: $90
Current: $39.68
Upside: +126.81%
Olema Pharmaceuticals
Oct 8, 2025
Initiates: Buy
Price Target: $20
Current: $8.35
Upside: +139.52%
Celcuity
Sep 22, 2025
Initiates: Buy
Price Target: $110
Current: $74.52
Upside: +47.61%
ORIC Pharmaceuticals
Sep 4, 2025
Assumes: Buy
Price Target: $18
Current: $12.35
Upside: +45.75%
Relay Therapeutics
Sep 4, 2025
Assumes: Buy
Price Target: $15
Current: $6.05
Upside: +147.93%
Nuvalent
Sep 4, 2025
Assumes: Buy
Price Target: $122
Current: $93.35
Upside: +30.69%
C4 Therapeutics
Sep 4, 2025
Initiates: Buy
Price Target: $8
Current: $2.34
Upside: +241.88%
Sep 4, 2025
Initiates: Buy
Price Target: $72
Current: $26.48
Upside: +171.90%
Sep 4, 2025
Initiates: Neutral
Price Target: n/a
Current: $9.86
Upside: -
Sep 4, 2025
Initiates: Buy
Price Target: $8
Current: $3.89
Upside: +105.66%
Mar 31, 2021
Initiates: Neutral
Price Target: $450
Current: $8.41
Upside: +5,250.77%
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $16.46
Upside: +234.14%
Mar 31, 2021
Initiates: Outperform
Price Target: $30
Current: $40.81
Upside: -26.49%